Mirion Technologies reported total revenue of $925.4 million for fiscal 2025, up 7.5% from $860.8 million in 2024. Adjusted EBITDA rose to $227.9 million, a 12% increase, and the company achieved a 24.6% margin, up from 23.7% the previous year.
For the fourth quarter, revenue was $277.4 million, a 9.1% year‑over‑year gain, while adjusted earnings per share were $0.15, falling short of the consensus estimate of $0.16 by $0.01. GAAP net earnings per share were $0.07.
Growth was driven by the nuclear and medical segments, which benefited from record orders and a strengthening nuclear power super cycle. The medical segment saw increased demand for radiation safety in cancer care, while the nuclear segment expanded its portfolio of monitoring solutions.
Management guided for 2026 total revenue growth of 22%–24%, organic revenue growth of 5%–7%, adjusted EBITDA of $285 million–$300 million, and adjusted free cash flow of $155 million–$175 million. Adjusted EPS guidance of $0.50–$0.57 falls short of the consensus estimate of $0.57, reflecting a cautious view of near‑term earnings.
Investors reacted to the earnings miss and lower EPS guidance, with the stock falling 4.3% in after‑hours trading. Analysts noted that while the company’s revenue trajectory remains positive, the slight shortfall in earnings and guidance signals management’s concern about potential cost pressures and the need to maintain margin discipline.
Thomas Logan, Chairman and CEO, said the company “delivered on its Adjusted EBITDA and Adjusted Free Cash Flow targets” and highlighted the record orders pipeline of over $1 billion, underscoring confidence in continued growth amid a favorable market environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.